With the U.S. introduction of anti-cancer biosimilars in 2019, understanding patient perceptions became vital. Ready to Launch Research partnered with a leading cancer support nonprofit to explore how cancer patients and caregivers comprehend and evaluate biosimilar therapies. The goal was to support healthcare decision-making through accessible, trustworthy resources.
From 2019 to 2021, we conducted iterative oncology qualitative research using focus groups and online discussion boards. The sample (N=35) included cancer survivors and caregivers. Participants reviewed draft educational materials and provided feedback on concepts like: "What is a biosimilar?", safety, manufacturing processes, and drug efficacy.
Insights led to the redesign of a patient-friendly booklet, infographic, and two educational videos. Research revealed patients wanted clearer explanations distinguishing biosimilars from generics and biologics, and guidance on whom to consult. This nonprofit health communication study improved biosimilar understanding and empowered patients to engage in treatment decisions. The final materials were distributed via Cancer Support Community affiliates and online at CancerSupportCommunity.org.
